Reproductive Health and HIV Research Unit *
* *
> search site
> site map
> contact us
> link to us
RHRU is a WHO collaborating centre

A multi-centred randomised trial of therapeutic intervention at primary HIV-1 infection (also known as SPARTAC)

Project Focus
HIV/AIDS; Primary HIV Infection; HIV treatment

Project Location
Soweto, Johannesburg

Duration of Project
2005 – 2010

Project Partners
Imperial College

Project Donors

Wellcome Trust via Imperial College of Science, Technology & Medicine, UK

Dr Sibongile Walaza

Project Aims /Objectives

To determine the effect of two anti-HIV treatment schedules of limited duration in PHI on the rate of CD4 cell decline and, consequently, on the time to initiating long-term anti-HIV therapy.

Secondary Objective:
To evaluate the effect of different durations of treatment during PHI on HIV-specific immune response and disease progression.

Project Activities
It is planned to recruit 360 individuals internationally, (from sites in Australia, South Africa and the UK), over a period of 18 months. The duration of intervention at PHI is a maximum of 48 weeks, and all patients will be followed up for a minimum of 30 months, making a trial duration of 5 years.

Participants will be randomly allocated in a 1:1:1 ratio at trial entry to start one of the regimens of open treatment with:
  • Arm A: Long course combination antiretroviral therapy (LCART) for 48 weeks
  • Arm B: Short course combination antiretroviral therapy (SCART) for 12 weeks
  • Arm C: No antiretroviral therapy

Anticipated/Actual Results
To provide direct evidence for or against treating primary HIV infection with anti retrovirals .

The primary efficacy endpoint will be the time from randomisation to reaching a CD4 of <350 cells/μl measured on two consecutive occasions not more than 4 weeks apart (not within first 3 months of trial entry).

The secondary efficacy outcomes will include:
  • HIV-specific CD4+ and CD8+ T-cell responses at week 60
  • Slope of CD4 decline
  • Time from randomisation to virological failure of first regimen of late treatment (LTX) or death
  • Development of drug resistance not present at baseline, before starting LTX or at week 120 whichever is earlier
  • Time from randomisation to the initiation of late treatment (LTX)
  • Differences in blood pressure from randomisation at week 12 and week
Additional Outputs

Future Plans
Further research on early HIV treatment regimens

Projects in the STI's & HIV Research Cluster:

Comment On Page | Tell A Friend | Bookmark | Print Page

designed by litmus digital